Clinical trialNo phase (not a drug trial)Completed
Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer
A Phase I Trial of Proton and Carbon Ion Radiation Dose Escalation in Patients With Locally Advanced Pancreatic Cancer
- Outcome
- Finished, no results posted
- Phase
- No phase (not a drug trial)
- Status
- Completed
- Study type
- Interventional
- Start
- 1 May 2015
- Ended
- 31 October 2016
- Enrollment
- 10 participants
- Sites
- 1
- Primary outcomes
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 5 March 2020
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to evaluate the toxicity and tolerance of proton and carbon ion radiotherapy (PCRT) for locally advanced pancreatic carcinoma (LAPC)
Detailed description public domain (ClinicalTrials.gov)
The proton dose of 50.4GyE in 28 fractions was delivered to clinical target volume (CTV), and carbon ion as a boost dose to gross tumor volume (GTV) escalated from 12GyE to 18GyE with 3GyE per fraction in 3 dose levels. The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were the endpoints.